Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
1.582
-0.088 (-5.27%)
Oct 10, 2025, 1:26 PM EDT - Market open
Sunshine Biopharma Employees
Sunshine Biopharma had 52 employees as of December 31, 2024. The number of employees increased by 8 or 18.18% compared to the previous year.
Employees
52
Change (1Y)
8
Growth (1Y)
18.18%
Revenue / Employee
$698,880
Profits / Employee
-$121,281
Market Cap
7.21M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 52 | 8 | 18.18% |
Dec 31, 2023 | 44 | -2 | -4.35% |
Dec 31, 2022 | 46 | 43 | 1,433.33% |
Dec 31, 2021 | 3 | 0 | - |
Dec 31, 2020 | 3 | 0 | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SBFM News
- 1 day ago - Sunshine Biopharma and University of Arizona Develop a Potent New Series of Protease Inhibitors for Treatment of SARS Coronavirus Infections - Accesswire
- 3 months ago - Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market - Accesswire
- 4 months ago - Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market - Accesswire
- 5 months ago - Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year - Accesswire
- 5 months ago - Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market - Accesswire
- 6 months ago - Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion - Accesswire
- 6 months ago - Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering - Accesswire
- 6 months ago - Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules - Accesswire